Induction of Cell Shape Changes through Activation of the Interleukin-3 Common beta  Chain Receptor by the RON Receptor-type Tyrosine Kinase*

Akihiko Mera, Moritaka Suga, Masayuki Ando, Toshio Suda, and Naoto Yamaguchi

From the First Department of Internal Medicine, 2Department of Cell Differentiation, Institute of Molecular Embryology and Genetics, Kumamoto University School of Medicine Kumamoto 860-0811, Japan

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The RON receptor-type tyrosine kinase, a member of the hepatocyte growth factor receptor family, is a receptor for macrophage-stimulating protein (MSP). Recently, we observed that MSP induces morphological changes in interleukin (IL)-3-dependent Ba/F3 cells ectopically expressing RON. We show here that stimulation of those cells with either MSP or IL-3 increases tyrosine phosphorylation of proteins of 130, 110, 90, 62, and 58 kDa and induces similar morphological changes, accompanied by unique nuclear shape and redistribution of F-actin. A tyrosine kinase inhibitor, genistein, blocked both the increase in tyrosine phosphorylation and morphological changes. Upon stimulation with either MSP or IL-3, prominent tyrosine-phosphorylated pp90 was similarly co-immunoprecipitated with the common beta  chain of IL-3 receptor (beta c). Unlike IL-3, stimulation with MSP increased tyrosine phosphorylation of beta c without activation of JAK2, resulting in morphological changes with modest cell growth. Confocal immunofluorescence analyses showed colocalization of RON, beta c, and tyrosine-phosphorylated proteins. In vitro kinase assays revealed that autophosphorylated RON phosphorylated beta c. These results suggest that the signaling pathway for morphological changes through beta c and its associated protein pp90 is distinct from the pathway for cell growth in the IL-3 signal transduction system.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Receptor-type tyrosine kinases (RTKs)1 play a critical role in pleiotropic cell functions such as proliferation and differentiation (1, 2). All RTKs are composed of three major domains, an extracellular ligand binding domain, a single membrane-spanning domain, and a cytoplasmic domain that contains a tyrosine kinase catalytic domain (3, 4). After ligand binding, RTKs undergo dimerization leading to activation of their intrinsic tyrosine kinase activity and autophosphorylation (5). The tyrosine-phosphorylated regions of the receptor function as high-affinity binding sites for proteins containing Src homology 2 and phosphotyrosine-binding domains, which transduce recep tor-generated signals upon phosphorylation (1, 2, 6).

The RON receptor-type tyrosine kinase is a member of a subfamily of RTK that includes the c-Met hepatocyte growth factor receptor and c-Sea (7). The human RON gene was cloned from human keratinocytes (8), and the mouse homolog, formerly known as STK (stem cell-derived tyrosine kinase), was derived from mouse hematopoietic stem cells (9). RON, as well as the hepatocyte growth factor receptor, is synthesized as a single-chain precursor, then cleaved to a mature disulfide-linked heterodimer composed of an extracellular alpha  chain and a transmembrane beta  chain with intrinsic tyrosine kinase activity (10, 11). RON has been identified as a receptor for macrophage-stimulating protein (MSP) and binding of MSP to RON stimulates autophosphorylation of RON to transmit signals intracellularly (10-13).

MSP is an 80-kDa serum protein that belongs to a family characterized by the presence of a highly conserved triple disulfide loop structure (Kringle domain). The family includes prothrombin, plasminogen, urokinase, and hepatocyte growth factor (14-17). MSP was shown to induce murine resident peritoneal macrophages to become responsive to chemoattractant C5a (18). MSP has multiple biological effects. In murine resident peritoneal macrophages it induces cell spreading and migration (18), direct chemotaxis (19), stimulates ingestion of complement-coated erythrocytes (15), and inhibits endotoxin- or cytokine-induced expression of inducible nitric oxide synthase mRNA (20). MSP also plays roles in chemotaxis of keratinocytes (21), bone resorption in osteoclasts (22), and in ciliary motility in bronchial epithelial cells (23).

It has been established that the IL-3 receptor shares a common beta  (beta c) subunit with the IL-5 receptor and the granulocyte/macrophage colony-stimulating factor (GM-CSF) receptor and that each receptor is composed of a unique alpha  subunit and the beta c subunit (24-26). Each alpha  subunit specifically exhibits low-affinity binding to IL-3, IL-5, or GM-CSF, whereas the beta c subunit lacks direct ligand binding but confers high affinity binding to the alpha  subunit. Binding of IL-3 to its receptor complex induces activation of the JAK2 tyrosine kinase. In turn, autophosphorylated JAK2 kinase activates beta c to recruit various signaling molecules to the tyrosine-phosphorylated beta c and triggers signal transduction events mediated by the cytoplasmic domain of beta c (27-30).

Recently, we found that stimulation with MSP induces cell growth through phosphorylation of two C-terminal tyrosine residues in the multifunctional docking site of RON (31). Stimulation with MSP also induces cell shape changes (11). To gain further insight into signal transduction events required for morphological changes and cell growth, we have compared MSP- and IL-3-induced tyrosine phosphorylation in IL-3-dependent Ba/F3 cells that ectopically express RON on the cell surface. Binding of MSP to RON activates beta c without activation of JAK2 to produce morphological changes. Our findings suggest that IL-3 stimulation activates two distinct signaling pathways, one involved in morphological changes and the other in cell growth.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Reagents and Antibodies-- Recombinant human MSP and recombinant mouse IL-3 were kindly provided by Drs. M. Hagiya and T. Takehara (Toyobo Co. Ltd, Shiga, Japan) and Dr. T. Sudo (Toray Industries, Inc., Kamakura, Japan), respectively. A rabbit polyclonal and a biotinylated rat monoclonal antibody against RON recognize the intracellular C-terminal region and the extracellular domain, respectively (11). Anti-phosphotyrosine (4G10 and FITC-conjugated 4G10) and anti-mouse JAK2 were obtained from Upstate Biotechnology, Inc. (Lake Placid, NY). Anti-mouse beta  chain common to IL-3, IL-5, and GM-CSF receptors (beta c), and Texas red-conjugated streptavidin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and PharMingen (San Diego, CA), respectively. Horseradish peroxidase-conjugated F(ab')2 fragments of anti-mouse Ig and of anti-rabbit Ig (Amersham Pharmacia Biotech) and rhodamine-phalloidin (Molecular Probe, Eugene, OR) were also used.

Plasmids and Cells-- cDNAs for murine full-length RON and RON-F1330/F1337, carrying combined mutations of tyrosine 1330 and 1337 to phenylalanine, were described previously (31). The murine IL-3-dependent pro-B cell line Ba/F3 stably expressed with either wild-type RON or RON-F1330/F1337 was cultured in serum-free medium containing 100 units/ml IL-3, as described (31).

Morphological Changes-- Wild-type RON- or RON-F1330/F1337-expressing Ba/F3 cells were deprived of IL-3 for 12 h before stimulation. Cells were adjusted to 1.6 × 105 cells/ml in RPMI 1640 medium supplemented with 25 mM HEPES, pH 7.2, and 0.1% bovine serum albumin (BSA), preincubated in the presence of 1 mM Na3VO4 for 5 min, and then stimulated with 100 ng/ml MSP or 100 units/ml IL-3 in the presence of 1 mM Na3VO4 for the indicated periods at 30 °C. Treatment of cells with Na3VO4 specifically enhanced MSP- or IL-3-induced morphological changes. Morphological changes were quantitated by counting the number of cells characterized by distortion, bending, stretching, and branching of the cell body under a phase-contrast microscope in three randomly selected high-power fields (magnification, ×200). Cells having filopodia and lamellipodia around the cell periphery were not counted. For treatment with various inhibitors, cells (1.6 × 105 cells/ml) were pretreated with various concentrations of genistein dissolved in 0.25% Me2SO, 20 µg/ml actinomycin D, or 10 µg/ml cycloheximide in 0.5% ethanol at 37 °C for 30 min, and then stimulated with MSP or IL-3 as described above. Murine bone marrow cells were obtained from C57BL/6 mice and long-term cultured in alpha -minimum essential medium containing 10% fetal bovine serum in the presence of 100 units/ml IL-3 for 14 days. Cells were deprived of IL-3 for 7 h and then stimulated with 100 units/ml IL-3 for 1 h at 37 °C.

Immunofluorescence-- Cells (1.6 × 105 cells/ml) were stimulated with MSP or IL-3 as described above. The cells were fixed with 3.7% paraformaldehyde at room temperature for 20 min. After washing, the cells were permeabilized with phosphate-buffered saline containing 3% BSA and 0.1% saponin for 20 min, as described (32), and then stained with rhodamine-phalloidin for F-actin or propidium iodide for nuclei. For detection of colocalization of tyrosine-phosphorylated proteins and RON, cells were fixed as above, blocked with phosphate-buffered saline containing 3% BSA for 20 min, and then stained with biotinylated anti-RON for 1 h. After permeabilized with saponin, the cells were stained with FITC-conjugated anti-phosphotyrosine antibody for 1 h and Texas red-conjugated streptavidin for 30 min. To prevent dephosphorylation, 10 mM Na3VO4 was included throughout the staining procedure, as described (33). To detect colocalization of RON and beta c, cells were fixed as above, blocked with phosphate-buffered saline containing 3% BSA for 20 min, and then stained with biotinylated rat anti-RON for 1 h, followed by staining with Texas red-conjugated streptavidin for 30 min. After permeabilization with saponin, cells were stained with anti-beta c for 30 min, followed by staining with FITC-conjugated anti-rabbit IgG for 30 min. FITC-anti-rabbit IgG was not cross-reactive with the rat anti-RON antibody. Confocal and Nomarski differential-interference-contrast images were obtained using a Fluoview laser scanning microscope (Olympus, Tokyo, Japan). Z-series sections were recorded at 0.5-µm intervals and merged. To ensure no bleed-through from the fluorescein signal into the red channel, fluorescein and Texas red fluorochromes were independently excited at 488 nm and 568 nm, respectively. Emission signals were detected at between 510 and 550 nm for fluorescein, more than 585 nm for Texas red, and more than 610 nm for propidium iodide.

Cell Migration Assay-- 50 µl of cell suspension (1 × 106 cells/ml in RPMI 1640 medium supplemented with 25 mM HEPES, pH 7.2, and 0.1% BSA) in triplicate were placed in the top wells of a 48-well microchemotaxis chamber (NeuroProbe Inc., Cabin John, MD). The lower wells, separated by a 5-µm pore polycarbonate membrane, were filled with 30 µl of 100 ng/ml MSP, 100 units/ml IL-3, or medium alone. After incubation at 37 °C for 3 h, cells migrating through the membrane were fixed and stained with May-Giemsa. The cells were counted under a microscope in five randomly selected high-power fields (magnification, ×400). Results were expressed as cell number/5 high-power fields (5 hpf).

Detection of Tyrosine Phosphorylation by Western Blotting and Immunoprecipitation-- Cells (2 × 107 cells/ml) were stimulated in the presence of 1 mM Na3VO4 at 30 °C as described above, unless stated. The cells were washed with HEPES-buffered saline (50 mM HEPES, pH 7.2, 150 mM NaCl and 10 mM Na3VO4) at 4 °C, and then lysed with Triton X-100 lysis buffer (50 mM HEPES, pH 7.4, 1% Triton X-100, 4 mM EDTA, 100 mM NaF, and 10 mM Na3VO4) containing 50 µg/ml aprotinin, 200 µM leupeptin, 50 µM pepstatin A, and 2 mM phenylmethylsulfonyl fluoride at 4 °C. Lysates were subjected to SDS-polyacrylamide gel electrophoresis and electrotransferred onto polyvinylidene difluoride membranes. Immunodetection was performed by enhanced chemiluminescence, as described (31, 34, 35). Immunoprecipitations were performed with anti-RON, anti-beta c, and anti-JAK2, and the immune complexes were washed with Triton X-100 lysis buffer at 4 °C and analyzed as described (31, 34, 35).

In Vitro Kinase Assay-- Protein G-Sepharose beads (Pharmacia) were precoated with both anti-RON reactive to the epitope in the extracellular domain of RON and anti-beta c antibodies. First, beta c was immunoprecipitated from the Triton X-100 lysate of parental Ba/F3 cells on the precoated beads. After washing with Triton X-100 lysis buffer, RIPA buffer (50 mM HEPES, pH 7.4, 1% Triton X-100, 4 mM EDTA, 1% deoxycholate, 0.1% SDS, 10 mM Na3VO4), and Triton X-100 lysis buffer containing M NaCl, the beads were incubated with equal amounts of Triton X-100 lysates of either COS-7 cells or COS-7 cells transiently transfected with RON. RON kinase expressed in COS-7 cells was highly autophosphorylated without exposure to MSP, probably due to aggregation of abundantly expressed RON. After washing as above, equal amounts of each immunoprecipitate were subjected to in vitro kinase assays. The immunoprecipitates were suspended with 70 µl of kinase buffer (50 mM HEPES, pH 7.4, 0.1% Triton X-100, 5 mM MgCl2, and 5 mM MnCl2) containing 0.2 mM Na3VO4 and 100 µM ATP. After incubation at 30 °C for the indicated periods, reactions were terminated by addition of 2× SDS sample buffer and boiling for 3 min. SDS-polyacrylamide gel electrophoresis and immunodetections were performed as described above. Phosphorylated bands detected with anti-pTyr (4G10) were quantified with a densitometer (ATTO, Tokyo).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Morphological Changes Induced by MSP or IL-3-- It is often observed that exposure of bone marrow cells and IL-3-dependent cell lines to IL-3 leads to changes in cell morphology and cell growth. Fig. 1A shows an example of cell shape changes of IL-3-dependent long-term cultured bone marrow cells. Our previous finding (11) indicates that MSP stimulation induces morphological changes in the IL-3-dependent pro-B cell line Ba/F3 ectopically expressing wild-type RON. We therefore compared the effects of MSP and IL-3 on cell morphology in these cells. MSP and IL-3 were found to induce similar morphological changes. A decrease in incubation temperature from 37 to 30 °C and addition of Na3VO4, a tyrosine phosphatase inhibitor, increased the proportion of cells morphologically changed (Fig. 1B, upper panels). Morphological changes were detected at 15 min and peaked at ~60 min of stimulation (data not shown). Phosphorylation of two C-terminal tyrosine residues, Tyr-1330 and Tyr-1337, in the multifunctional docking site of RON plays a critical role in RON-mediated signal transduction (31). Surprisingly, cells expressing RON-F1330/F1337, which carried mutations of tyrosine 1330 and 1337 to phenylalanine, responded to MSP with striking changes of morphology (lower panels).


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 1.   Morphological changes accompanied by F-actin reorganization upon stimulation with MSP or IL-3. A, phase-contrast micrographs of IL-3-dependent long-term cultured bone marrow cells. Cells were cultured in the presence of 100 units/ml IL-3 at 37 °C (a). The cells became round after IL-3 deprivation for 7 h (b) and were restimulated with 100 units/ml IL-3 for 1 h (c). Arrowheads indicate cells morphologically changed. Bar, 20 µm. B, phase-contrast micrographs of either wild-type RON- or RON-F1330/F1337-expressing Ba/F3 cells. Cells deprived of IL-3 for 12 h were stimulated with 100 ng/ml MSP (b and e) or 100 units/ml IL-3 (c and f) in the presence of 1 mM Na3VO4 for 1 h at 30 °C after preincubation with 1 mM Na3VO4 for 5 min at 30 °C as described under "Experimental Procedures." Bar, 20 µm. C, Nomarski differential-interference-contrast and con-focal fluorescence microscopic analyses of either wild-type RON- or RON-F1330/F1337-expressing Ba/F3 cells. After stimulation with 100 ng/ml MSP, 100 units/ml IL-3, or medium alone as above, cells were stained with propidium iodide for nuclei and rhodamine-phalloidin for F-actin. Bar, 5 µm.

To characterize MSP- or IL-3-induced shape changes, cells were stained with propidium iodide for nuclei and rhodamine-phalloidin for F-actin, and analyzed by Nomarski differential-interference-contrast and confocal fluorescence microscopy. Fig. 1C shows that stimulation with MSP or IL-3 induced drastic morphological changes accompanied by unique nuclear shape changes and redistribution and an increase in F-actin. Most cells showed uropod-like structures. Note that lobulated nuclei were preferentially observed upon MSP stimulation, suggesting that the activity of MSP is stronger than that of IL-3. These results indicate that MSP and IL-3 induce similar shape changes, and that MSP-induced shape changes are not mediated through the multifunctional docking site of RON.

Blockade of MSP- or IL-3-induced Shape Changes by Genistein-- Tyrosine phosphorylation is involved in MSP and IL-3 signaling. We examined whether genistein, a tyrosine kinase inhibitor, blocked morphological changes. Treatment of wild-type RON-expressing cells with genistein inhibited both MSP- and IL-3-induced morphological changes, whereas genistein alone had no effect on morphology and viability (Fig. 2, A and B). Another tyrosine kinase inhibitor, herbimycin A (20 µg/ml), also blocked morphological changes (data not shown). Morphological changes were not inhibited by actinomycin D (ActD), an RNA synthesis inhibitor, or cycloheximide (CHX), a protein synthesis inhibitor (Fig. 2B, a). MSP was more potent than IL-3 in both cell types (Fig. 2B, a and b), and the proportion of cells morphologically changed in RON-F1330/F1337-expressing cells was larger than that observed in wild-type RON-expressing cells (data not shown). In RON-F1330/F1337-expressing cells, morphological changes were also blocked by genistein (Fig. 2B, b). These results indicate that tyrosine phosphorylation is required for morphological changes.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of genistein on MSP- or IL-3-induced morphological changes. A, phase-contrast micrographs of wild-type RON-expressing cells. Cells deprived of IL-3 for 12 h were pretreated with Me2SO alone (upper panels) or 50 µg/ml genistein (lower panels) for 30 min and then stimulated with MSP or IL-3 in the presence of Me2SO or genistein as described in Fig. 1. Bar, 20 µm. B, quantification of morphological changes. Wild-type RON-expressing cells (a) were stimulated with MSP (hatched bars), IL-3 (stippled bars), or medium alone (open bars) for 1 h as described in Fig. 1. The number of cells morphologically changed in the presence of the indicated concentrations of genistein (µg/ml), 20 µg/ml actinomycin D (ActD) and 10 µg/ml cycloheximide (CHX) were examined in three randomly selected high-power fields (magnification, ×200). The results represent the mean ± S.D. from three different experiments (%). RON-F1330/F1337-expressing cells (b) were pretreated with Me2SO alone or 50 µg/ml genistein for 30 min and then stimulated for 30 min as above. The results represent the mean ± S.D. from three different experiments (%).

Tyrosine Phosphorylation of Cellular Proteins Induced by MSP or IL-3-- To determine whether MSP or IL-3 induced tyrosine phosphorylation of cellular proteins, Western blotting was performed using the anti-phosphotyrosine mAb 4G10 (Fig. 3). Stimulation of wild-type RON-expressing cells with MSP increased tyrosine phosphorylation of RON at 145 kDa and of proteins at 130, 110, 90, 62, and 58 kDa (Fig. 3A). A similar increase in tyrosine phosphorylation of proteins at 130, 110, 90, 62, and 58 kDa was observed upon stimulation with IL-3. Tyrosine phosphorylation of RON per se was not induced by stimulation with IL-3. Addition of Na3VO4 to cell suspensions throughout stimulation periods and the decrease in reaction temperature from 37 °C (Fig. 3A, lanes 4-6) to 30 °C (lanes 1-3) enhanced increases in the level of MSP- or IL-3-induced tyrosine phosphorylation probably due to inhibition of rapid dephosphorylation. These results are consistent with the morphological observations (Figs. 1 and 2) and suggest that RON-mediated signaling is closely related to the IL-3-induced signaling through tyrosine phosphorylation.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 3.   Tyrosine phosphorylation of cellular proteins induced by MSP or IL-3. A, Western blots of equal amounts of Triton X-100 lysates from wild-type RON-expressing cells stimulated with MSP or IL-3 at 30 °C (lanes 1-3) and 37 °C (lanes 4-6) for 15 min in the presence of 1 mM Na3VO4 as described under "Experimental Procedures," probed with anti-pTyr (4G10) (upper panels) and reprobed with rabbit anti-RON (lower panels). In the RON blot, the upper band represents the cytoplasmic single-chain precursor of RON. B, the upper panel shows pp90 (pp86, pp87, pp91, and pp94) upon stimulation with medium alone (lane 1), MSP (lane 2), and IL-3 (lane 3); the lower panel shows schematic locations of pp90 subspecies (pp86, pp87, pp91, and pp94).

In addition, increased levels of tyrosine phosphorylation were apparent 5 min after stimulation, peaked at 15 min, and sustained for at least 60 min of stimulation (data not shown). These kinetics suggest that MSP- or IL-3-induced tyrosine phosphorylation precedes morphological changes. Furthermore, the levels of tyrosine phosphorylation induced by MSP were generally higher than those induced by IL-3, consistent with observations that MSP was more potent than IL-3 in promoting morphological changes (Fig. 2). pp90 was a prominent tyrosine-phosphorylated protein consisting of four subspecies (pp86, pp87, pp91, and pp94) (Fig. 3B, upper panel). Fig. 3B (lower panel) represents schematic locations of pp90 subspecies.

Interaction of RON with the Common beta  Chain of IL-3 Receptor (beta c)-- Because treatment with genistein inhibited MSP- or IL-3-induced morphological changes (Fig. 2), we examined whether genistein indeed inhibited MSP- or IL-3-induced tyrosine phosphorylation in both wild-type RON- (Fig. 4, A-C) and RON-F1330/F1337-expressing cells (E-G). Tyrosine phosphorylation was similarly induced in both cell types, and treatment with genistein inhibited increases in tyrosine phosphorylation of RON, pp130, pp110, pp90, pp62, and pp58 (Fig. 4, A and E). Inhibition of RON autophosphorylation (B and F) indicates that RON kinase activity is repressed by genistein.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 4.   MSP-induced tyrosine phosphorylation of beta c. Panels A and E, Western blots of equal amounts of Triton X-100 lysates from either wild-type RON- or RON-F1330/F1337-expressing cells, probed with anti-pTyr. Cells deprived of IL-3 for 12 h were pretreated with Me2SO alone (lanes 1-3) or 50 µg/ml genistein (lanes 4-6), and then stimulated with MSP or IL-3 as described in Fig. 2. Panels B-D and F-H, Western blots of RON, beta c, and JAK2 immunoprecipitates from the Triton X-100 lysates, probed with anti-pTyr and reprobed with respective antibodies.

The common beta  chain of IL-3 receptor (beta c) is known to play a pivotal role in signal transduction mediated by the IL-3 receptor system (27). Because beta c appeared to correspond to pp130 on anti-beta c blots (data not shown; see Figs. 3A and 4, A and E), we therefore examined whether beta c is involved in RON-mediated signaling. Fig. 4, C and G show by immunoprecipitation that MSP, like IL-3, induced an increase in tyrosine phosphorylation of the beta c doublet. The levels of beta c tyrosine phosphorylation induced by MSP were generally higher than those induced by IL-3. In addition, MSP- or IL-3-induced tyrosine phosphorylation of beta c was inhibited by genistein (Fig. 4, C and G, lanes 4-6).

IL-3-induced receptor aggregation initiates autophosphorylation and activation of JAK2 tyrosine kinase, and activated JAK2 in turn phosphorylates beta c to recruit various signaling molecules (36). We analyzed an increase in tyrosine phosphorylation of JAK2. Fig. 4, D and H show that MSP, unlike IL-3, was unable to increase tyrosine phosphorylation of JAK2, suggesting that activation of JAK2 is not required for RON-mediated signaling.

To examine whether RON kinase could directly tyrosine-phosphorylate beta c, an in vitro kinase assay was performed with RON kinase immunoprecipitated from RON-transfected COS-7 cells. Fig. 5, A and B show that tyrosine phosphorylation of beta c was clearly detected at 5 min (Fig. 5A, lane 5), and increased at 30 min (lane 6), whereas an increase in tyrosine phosphorylation of beta c was not detected at 0 min (lane 4). beta c was not tyrosine-phosphorylated without RON kinase (lanes 1-3). These results suggest that RON kinase could directly tyrosine-phosphorylate beta c.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 5.   Tyrosine phosphorylation of beta c by RON kinase in vitro. A, beta c immunoprecipitates were incubated with (lanes 4-6) or without (lanes 1-3) RON kinase in reaction buffer containing 100 µM ATP. Samples were taken at the indicated times. Western blot of each sample was probed with anti-pTyr (upper panel) and reprobed with anti-beta c (middle panel) and anti-RON (lower panel). B, phosphorylated bands of beta c detected with anti-pTyr were quantified by densitography. The levels of tyrosine phosphorylation at each incubation time (5 and 30 min) relative to that of the control (0 min) are shown.

Interaction among RON, beta c, and pp90-- To examine whether beta c could associate with tyrosine-phosphorylated proteins, co-immunoprecipitation analyses were performed with Triton X-100 lysates obtained from wild-type RON-expressing cells. We found that beta c was specifically co-immunoprecipitated with pp90 but not with pp62 and pp58 (Fig. 6A; data not shown). Three pp90 subspecies, pp87, pp91, and pp94, were co-immunoprecipitated with MSP- or IL-3-activated beta c, whereas pp86 was associated with control beta c. The degree of association of pp87, pp91, and pp94 with beta c corresponded to that of tyrosine phosphorylation of beta c (see Fig. 6, shorter exposure). Neither pp86, pp87, pp91, nor pp94 was identified as STAT5, Vav, the p85 subunit of phosphatidylinositol 3-kinase, or ezrin (data not shown). These results suggest that tyrosine-phosphorylated beta c forms a novel complex with pp90.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 6.   Association of beta c with pp90 and colocalization of beta c with RON. Panel A, Western blot of beta c immunoprecipitates from Triton X-100 lysates of wild-type RON-expressing cells, probed with anti-pTyr (upper panels) and anti-beta c (lower panel). Cells were stimulated with medium alone (lanes 1 and 1'), MSP (lanes 2 and 2'), and IL-3 (lanes 3 and 3'), as described in Fig. 1. A shorter exposure of the film is shown on the right. Asterisks indicate the positions of pp90 subspecies. Panels B and C, wild-type RON-expressing cells were stimulated with medium alone (upper panels) and MSP (lower panels) for 1 h as described in Fig. 1. After fixation, cells were double-stained with anti-pTyr (B) or anti-beta c (C) (green channel), together with anti-RON (B and C) (red channel), as described under "Experimental Procedures" and analyzed by Nomarski differentiation-interference-contrast and confocal immunofluorescence microscopy. The right panels show superimposed images of green and red channels. Arrowheads indicate the areas of colocalization of RON with tyrosine-phosphorylated proteins and of RON with beta c. Bar, 5 µm.

RON-mediated tyrosine phosphorylation of beta c suggests that RON, beta c, and tyrosine-phosphorylated proteins could be colocalized. To test this, confocal immunofluorescence microscopic analyses were performed. Fig. 6B (upper panels) shows a uniform distribution of tyrosine-phosphorylated proteins and RON in control cells. On the other hand, cells stimulated with MSP showed the redistribution and colocalization of RON and tyrosine-phosphorylated proteins as well as increases in tyrosine phosphorylation of cellular proteins. Colocalization of RON and tyrosine-phosphorylated proteins was prominently observed in regions containing many granules and uropod-like structures (Fig. 6B, arrowheads, lower panels). As shown in Fig. 6C, control cells showed colocalized beta c and RON in a uniform distribution. Interestingly, cells stimulated with MSP showed the redistribution and colocalization of RON and beta c. The pattern of colocalization of beta c with RON is similar to that of tyrosine-phosphorylated proteins and RON (arrowheads, lower panels), consistent with redistribution of F-actin upon stimulation (Fig. 1C). These results suggest that RON, beta c, and tyrosine-phosphorylated proteins are colocalized particularly in uropod-like regions of stimulated cells.

Cell Growth and Migration-- IL-3 induced a strong proliferative response in wild-type RON-expressing cells, whereas MSP-stimulated cells displayed modest growth responses or prolonged survival (Fig. 7). However, in RON-F1330/F1337-expressing cells, treatment with MSP or medium alone did not induce cell growth, whereas IL-3 stimulation induced a strong proliferative response (data not shown). These results are consistent with our previous demonstration that MSP stimulation results in modest growth responses (31).


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 7.   Cell growth. After IL-3 deprivation for 12 h, wild-type RON-expressing Ba/F3 cells were stimulated with MSP or IL-3 as described in Fig. 1. Viable cells were counted by trypan blue exclusion, and the data represent the mean ± S.D. from three different experiments.

MSP is reported to induce chemotactic responses of murine peritoneal macrophages and keratinocytes (19, 21). IL-3 has also been shown to act as a chemotactic factor for eosinophils (37). To examine the effects of MSP and IL-3 on chemotaxis, cell migration assays were performed. MSP and IL-3 induced cell migration toward respective stimulants. After 3 h of stimulation, numbers of migrating cells increased approximately 4-fold (205 ± 10 cells/5 hpf) and 2.8-fold (132 ± 25 cells/5 hpf) in response to MSP and IL-3, respectively, compared with medium alone (47 ± 23 cells/5 hpf). Cell migration to MSP or IL-3 was inhibited by 50 µg/ml genistein (control, 17 ± 4 cells/5 hpf; MSP, 27 ± 1 cells/5 hpf; IL-3, 21 ± 6 cells/5 hpf). Similar results were obtained in RON-F1330/F1337-expressing cells (data not shown). These results suggest that RON-mediated tyrosine phosphorylation of beta c underlying morphological changes contributes to migration but not to cell growth.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, we use IL-3-dependent cells ectopically expressing RON to characterize distinct pathways involved in cell growth and changes in morphology seen following IL-3 and MSP stimulation.

Our model for the mechanism of IL-3 receptor-mediated morphological changes is shown in Fig. 8. In unstimulated cells (Fig. 8A), ectopically expressed RON kinase localizes with the IL-3 receptor beta c. Neither JAK2 kinase that constitutively associates with beta c nor RON kinase is activated in the absence of IL-3 or MSP. When cells are stimulated with IL-3 (Fig. 8B), JAK2 is activated to phosphorylate both beta c at multiple sites and recruited STAT5 to trigger cell growth. Moreover, activation of JAK2 increases tyrosine phosphorylation of several proteins including pp90, which associates with beta c. When cells are stimulated with MSP (Fig. 8C), RON kinase activated by autophosphorylation triggers increased tyrosine phosphorylation of beta c and several proteins including pp90, resulting in morphological changes. In contrast to IL-3, MSP stimulation does not activate JAK2 or promote strong proliferative responses. Modest cell growth induced by MSP results from phosphorylation of two tyrosine residues in the multifunctional docking site of RON. pp90 is located downstream of activated JAK2 in the IL-3 signal transduction pathway. Activated RON kinase presumably phosphorylates p90 without activation of JAK2; this path leads to beta c-mediated morphological changes but not to proliferation.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 8.   A model for two distinct signaling pathways via beta c. Panel A, ectopically expressed RON tyrosine kinase localizes with beta c in unstimulated cells. Panel B, when IL-3 binds to its receptor that consists of alpha  and beta c chains, JAK2 tyrosine kinase is activated to phosphorylate beta c and STAT5 triggering cell growth. In addition, stimulation with IL-3 leads to morphological changes through tyrosine phosphorylation of beta c and its associated protein pp90. Panel C, when MSP binds to its receptor RON, RON kinase is activated through autophosphorylation. Subsequently, activated RON phosphorylates beta c and pp90 without activation of JAK2, leading to morphological changes. In contrast to IL-3, MSP stimulation does not activate JAK2 and induces modest cell growth probably due to tyrosine phosphorylation of two tyrosine residues in the multifunctional docking site of RON.

It has been well established that tyrosine phosphorylation of beta c is crucial for IL-3 signal transduction (24-30, 36, 38, 39). Binding of IL-3 to its receptor induces activation of JAK2 tyrosine kinase and triggers tyrosine phosphorylation of the cytoplasmic domain of beta c phosphorylation sites, resulting in recruitment of signaling proteins, such as STAT5 and c-Myc. Stimulation of the c-Kit receptor-type tyrosine kinase with the Kit ligand phosphorylates and activates the erythropoietin receptor, which associates with JAK2 (40). The activated beta  subunit of the IL-6 receptor and the ErbB2 receptor-type tyrosine kinase interact directly with each other (41). The results presented here provide another example of cross-talk between a receptor-type tyrosine kinase and a signal-transducing subunit/domain of the cytokine receptor family. Based on our observations of crosstalk between RON and beta c in cell shape changes, we hypothesize that ectopically expressed RON preferentially phosphorylates some of tyrosine residues on beta c that can be phosphorylated by activated JAK2 following stimulation with IL-3. Identification of the beta c tyrosine residues responsible for morphological changes will help further our understanding of this signaling pathway.

We recently showed that two C-terminal tyrosine residues, Tyr-1330 and Tyr-1337, in the multifunctional docking site of RON that are conserved among the hepatocyte growth factor family receptors are principally responsible for the signal transduction involved in cell growth (31). After MSP binds to RON, signaling molecules such as Shc, phospholipase Cgamma , phosphatidylinositol 3-kinase, Grb2, and others are recruited to the two C-terminal tyrosine phosphorylation sites. We therefore compared morphological changes and tyrosine phosphorylation in wild-type RON-expressing cells with those in RON-F1330/F1337-expressing cells. Surprisingly, the F1330/1337 mutation enhanced the morphological responses, indicating that the multifunctional docking site is not required. However, the kinase activity of RON is required for morphological changes.

Intriguingly, treatment of cells with Na3VO4 at 30 °C during stimulation periods greatly augments not only the morphological responses but also the level of tyrosine phosphorylation of cellular proteins, because this treatment prevents tyrosine-phosphorylated proteins from rapid dephosphorylation by a yet unidentified protein-tyrosine phosphatase(s). We have evidence that activity of a protein-tyrosine phosphatase(s) is tightly associated with RON (data not shown), although the site of interaction of RON with the phosphatase(s) is not known. It is possible that the F1330/1337 mutation enhances activity of a protein-tyrosine phosphatase(s) by an unknown mechanism. Moreover, treatment with the protein-tyrosine kinase inhibitors, genistein and herbimycin A, completely blocks the morphological changes observed in both wild-type RON-expressing or RON-F1330/F1337-expressing cells. The delicate balance between tyrosine phosphorylation and dephosphorylation of specific proteins plays an important role in MSP- or IL-3-induced morphological changes.

pp90 consists of 4 subspecies, pp86, pp87, pp91, and pp94. pp86 is associated with beta c in the unstimulated state. Upon stimulation with MSP or IL-3, pp87, pp91, and pp94 are tyrosine-phosphorylated and associated with beta c, and the levels of tyrosine phosphorylation of these proteins correspond to those of tyrosine phosphorylation of beta c. In addition, using sucrose density gradient fractionation analyses we found that pp90 was localized in the higher density lysate fractions at ~400 kDa (data not shown), consistent with the results that pp90 can form a protein complex with beta c. Treatment of cells with MSP relocates RON, beta c, and tyrosine-phosphorylated proteins to uropod-like structures where F-actin is redistributed and concentrated. These results suggest that phosphorylation of pp90 could control distribution and reorganization of actin filaments. Despite efforts to purify pp90, at present we are unable to immunoprecipitate pp90 with the anti-phosphotyrosine antibody 4G10, probably because phosphotyrosine residues are not exposed to the surface of the protein complex. Although we do not know that the migration of pp90 subspecies on SDS-polyacrylamide gels stems from one molecule having four different phosphorylation states or from four distinct molecules, identification of pp90 will help us more fully understand how activation of beta c initiates morphological changes.

Previous data with LyD9 IL-3-dependent pro-B cells, which ectopically express the IL-2 receptor, and FDC.P-1 IL-3-dependent hematopoietic precursor cells show that stimulation of the former with IL-3 or IL-2 and the latter with IL-3 induces tyrosine phosphorylation of an ~90-kDa protein accompanied by early cell shape changes and later cell growth (42). It is possible that the IL-2 receptor, which associates with JAK1 and JAK3, also interacts with beta c. Given that morphological change-related pp90 is induced in IL-3-dependent Ba/F3 cells, we hypothesize that a tyrosine-phosphorylated protein at ~90 kDa seen in other IL-3-dependent LyD9 and FDC.P-1 cells is identical to pp90 seen in Ba/F3 cells.

In conclusion, we have elucidated a novel IL-3 signaling pathway involving pp90, which associates with beta c, and leading to morphological changes and subsequent cell migration. Our findings demonstrate that the signaling events of this pathway are distinct from those required for cell growth. Cell migration is accompanied by induction of morphological changes (43). To move through small openings in various tissues, cells must be able to change their shapes drastically. Because the receptors for IL-3, IL-5, and GM-CSF each consist of a ligand-binding alpha  chain associated with a common signal transducer beta c chain (24-27), it is reasonable to predict that, in addition to IL-3 in immature hematopoietic cells, IL-5 and GM-CSF can induce pp90 required for morphological changes of eosinophils and neutrophils/macrophages, respectively.

    ACKNOWLEDGEMENTS

We are grateful to Drs. Michio Hagiya and Toyohiro Takehara (Toyobo Co. Ltd) and Dr. Tetsuo Sudo (Toray Industries, Inc) for generously providing MSP and IL-3.

    FOOTNOTES

* This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture, Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Radiobiochemistry, School of Pharmaceutical Sciences, University of Shizuoka, Yada 52-1, Shizuoka 422-8526, Japan. Tel.: 81-54-264-5703; Fax: 81-54-264-5705.

    ABBREVIATIONS

The abbreviations used are: RTKs, receptor-type tyrosine kinases; MSP, macrophage-stimulating protein; GM-CSF, granulocyte/macrophage colony-stimulating factor; IL, interleukin; FITC, fluorescein isothiocyanate; BSA, bovine serum albumin; hpf, high-power fields.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Schlessinger, J., and Ullrich, A. (1992) Neuron 9, 383-391[Medline] [Order article via Infotrieve]
  2. Pawson, T. (1995) Nature 373, 573-580[CrossRef][Medline] [Order article via Infotrieve]
  3. Hanks, S. K., Quinn, A. M., and Hunter, T. (1988) Science 241, 42-52[Medline] [Order article via Infotrieve]
  4. Yarden, Y., and Ullrich, A. (1988) Annu. Rev. Biochem. 57, 443-478[CrossRef][Medline] [Order article via Infotrieve]
  5. Weiss, A., and Schlessinger, J. (1998) Cell 94, 277-280[Medline] [Order article via Infotrieve]
  6. Cohen, G. B., Ren, R., and Baltimore, D. (1995) Cell 80, 237-248[Medline] [Order article via Infotrieve]
  7. Huff, J. L., Jelinek, M. A., Borgman, C. A., Lasing, T. J., and Parsons, J. T. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6140-6144[Abstract]
  8. Ronsin, C., Muscatelli, F., Mattei, M.-G., and Breathnach, R. (1993) Oncogene 8, 1195-1202[Medline] [Order article via Infotrieve]
  9. Iwama, A., Okano, K., Sudo, T., Matsuda, Y., and Suda, T. (1994) Blood 83, 3160-3169[Abstract/Free Full Text]
  10. Gaugino, G., Follenzi, A., Naldini, L., Collesi, C., Santoro, M., Gallo, K. A., Godowski, P. J., and Comoglio, P. M. (1994) EMBO J. 13, 3524-3532[Abstract]
  11. Iwama, A., Wang, M.-H., Yamaguchi, N., Ohno, N., Okano, K., Sudo, T., Takeya, M., Gervais, F., Morisette, C., Leonard, E. J., and Suda, T. (1995) Blood 86, 3394-3403[Abstract/Free Full Text]
  12. Wang, M.-H., Ronsin, C., Gesnel, M.-C., Coupey, L., Skeel, A., Leonard, E. J., and Breathnach, R. (1994) Science 266, 117-119[Medline] [Order article via Infotrieve]
  13. Wang, M.-H., Iwama, A., Skeel, A., Suda, T., and Leonard, E. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3933-3937[Abstract/Free Full Text]
  14. Han, S., Stuart, L. A., and Degen, S. J. F. (1991) Biochemistry 30, 9768-9780[Medline] [Order article via Infotrieve]
  15. Skeel, A., Yoshimura, T., Showalter, S. D., Tanaka, S., Appella, E., and Leonard, E. J. (1991) J. Exp. Med. 173, 1227-1234[Abstract]
  16. Yoshimura, T., Yuhki, N., Wang, M.-H., Skeel, A., and Leonard, E. J. (1993) J. Biol. Chem. 268, 15461-15468[Abstract/Free Full Text]
  17. Shimamoto, A., Kimura, T., Matsumoto, K., and Nakamura, T. (1993) FEBS Lett. 333, 61-66[CrossRef][Medline] [Order article via Infotrieve]
  18. Leonard, E. J., and Skeel, A. (1976) Exp. Cell. Res. 102, 434-438[Medline] [Order article via Infotrieve]
  19. Skeel, A., and Leonard, E. J. (1994) J. Immunol. 152, 4618-4623[Abstract/Free Full Text]
  20. Wang, M.-H., Cox, G. W., Yoshimura, T., Sheffler, L. A., Skeel, A., and Leonard, E. J. (1994) J. Biol. Chem. 269, 14027-14031[Abstract/Free Full Text]
  21. Wang, M.-H., Dlugosz, A. A., Sun, Y., Suda, T., Skeel, A., and Leonard, E. J. (1996) Exp. Cell. Res. 226, 39-46[CrossRef][Medline] [Order article via Infotrieve]
  22. Kurihara, N., Iwama, A., Tatsumi, J., Ikeda, K., and Suda, T. (1996) Blood 87, 3704-3710[Abstract/Free Full Text]
  23. Sakamoto, O., Iwama, A., Amitani, R., Takeya, T., Yamaguchi, N., Yamamoto, T., Masuyama, K., Yamanaka, T., Ando, M., and Suda, T. (1997) J. Clin. Invest. 99, 701-709[Abstract/Free Full Text]
  24. Takaki, S., Mita, S., Kitamura, T., Yonehara, S., Yamaguchi, N., Tominaga, A., Miyajima, A., and Takatsu, K. (1991) EMBO J. 10, 2833-2838[Abstract]
  25. Kitamura, T., Sato, N., Arai, K., and Miyajima, A. (1991) Cell 66, 1165-1174[Medline] [Order article via Infotrieve]
  26. Tavernier, J., Devos, R., Cornelis, S., Tuypens, T., Van der Heyden, J., Fiers, W., and Plaetinck, G. (1991) Cell 66, 1175-1184[Medline] [Order article via Infotrieve]
  27. Miyajima, A., Kitamura, T., Harada, N., Yokota, T., and Arai, K. (1992) Annu. Rev. Immunol. 10, 295-331[CrossRef][Medline] [Order article via Infotrieve]
  28. Sakamaki, K., Miyajima, I., Kitamura, T., and Miyajima, A. (1992) EMBO J. 11, 3541-3549[Abstract]
  29. Sato, N., Sakamaki, K., Terada, N., Arai, K., and Miyajima, A. (1993) EMBO J. 12, 4181-4189[Abstract]
  30. Kinoshita, T., Yokota, T., Arai, K., and Miyajima, A. (1995) EMBO J. 14, 266-275[Abstract]
  31. Iwama, A., Yamaguchi, N., and Suda, T. (1996) EMBO J. 15, 5866-5875[Abstract]
  32. Yamaguchi, N., and Fukuda, M. N. (1995) J. Biol. Chem. 270, 12170-12176[Abstract/Free Full Text]
  33. Tada, J., Omine, M., Suda, T., and Yamaguchi, N. (1999) Blood, in press
  34. Hirao, A., Hamaguchi, I., Suda, T., and Yamaguchi, N. (1997) EMBO J. 16, 2342-2351[Abstract/Free Full Text]
  35. Hirao, A., Huang, X. L., Suda, T., and Yamaguchi, N. (1998) J. Biol. Chem. 273, 10004-10010[Abstract/Free Full Text]
  36. Ihle, J. N. (1995) Nature 377, 591-594[CrossRef][Medline] [Order article via Infotrieve]
  37. Warringa, R. A. J., Koenderman, L., Kok, P. T. M., Kreukniet, J. K., and Bruijnzeel, P. L. B. (1991) Blood 77, 2694-2700[Abstract]
  38. Taniguchi, T. (1995) Science 268, 251-255[Medline] [Order article via Infotrieve]
  39. Ihle, J. N. (1996) Cell 84, 331-334[Medline] [Order article via Infotrieve]
  40. Wu, H., Klingmuller, U., Besmer, P., and Lodish, H. F. (1995) Nature 377, 242-246[CrossRef][Medline] [Order article via Infotrieve]
  41. Qiu, Y., Ravi, L., and Kung, H.-J. (1998) Nature 393, 83-85[CrossRef][Medline] [Order article via Infotrieve]
  42. Sabe, H., Kuno, J., Kolomilas, A., Saito, Y., Kinashi, T., Ueda, M., Takamatsu, T., Hamaguchi, M., Kawakami, T., and Honjo, T. (1991) Int. Immunol. 3, 1137-1148[Abstract]
  43. Bretscher, M. S. (1996) Cell 87, 601-606[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.